Evidence map›Paper›PMID 37074202›Full record

Trial reportHuman vaccines & immunotherapeutics2023

Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults.

Patrick Yassini, Mark Hutchens, Yamuna D Paila, Lorraine Schoch, Anne Aunins, Uma Siangphoe, Robert Paris

Open access · goldAbstract readRandomized Controlled TrialClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Human vaccines & immunotherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Patrick YassiniDepartment of Family and Preventive Medicine, University of California, San Diego, CA, USA.
Mark HutchensOptimal Research, Austin, TX, USA.
Yamuna D PailaInfectious Disease Development, Moderna, Inc., Cambridge, MA, USA.
Lorraine SchochInfectious Disease Development, Moderna, Inc., Cambridge, MA, USA.
Anne AuninsInfectious Disease Development, Moderna, Inc., Cambridge, MA, USA.
Uma SiangphoeInfectious Disease Development, Moderna, Inc., Cambridge, MA, USA.
Robert ParisInfectious Disease Development, Moderna, Inc., Cambridge, MA, USA.
Moderna Therapeutics (United States) · USOptimal Solutions (United States) · USUniversity of California, San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This interim analysis of an ongoing phase 1 randomized clinical trial evaluated the safety, reactogenicity, and immunogenicity of mRNA-1283, a next-generation SARS-CoV-2 messenger RNA (mRNA)-based vaccine encoding two segments of the spike protein (i.e. receptor binding and N-terminal domains). Healthy adults aged 18-55 years (

Indexed as

COVID-19COVID-19 Vaccines2019-nCoV Vaccine mRNA-1273AdultAntibodies, NeutralizingAntibodies, ViralDouble-Blind MethodHumansImmunogenicity, VaccineRNA, MessengerSARS-CoV-22019-nCoV Vaccine mRNA-1273Antibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesRNA, Messengerclinical studyCOVID-19mRNA vaccinesSevere acute respiratory syndrome coronavirus-2vaccination

Identifiers

PMID37074202
PMCPMC10128428
OpenAlexW4366351268

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.